

FLUIDIGM

Fluidigm Announces 8th Annual Mass Cytometry Summit

April 30, 2019

Fluidigm invites researchers to the world's largest global mass cytometry conference in Vancouver, Canada

SOUTH SAN FRANCISCO, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will hold the 8th Annual Fluidigm Mass Cytometry Summit on June 20 and 21, 2019, at the Pinnacle Hotel Harbourfront in Vancouver, Canada. The Summit brings together translational researchers from around the world to discuss new mass cytometry research applications and best practices for identifying biomarker signatures in health and disease and accelerating therapeutic development.

"We are excited to hold this year's Summit right before CYTO® 2019," said Chris Linthwaite, President and CEO of Fluidigm. "Our Annual Fluidigm Mass Cytometry Summit has emerged as the premier forum for highlighting scientific advances and technology development within the mass cytometry community. Bringing global mass cytometry researchers together accelerates the cross-pollination of best practices, the creation of new collaborations and the education of the broader community."

"We have a great two-day program planned this year with more than 25 scientific and technical presentations by experts covering multiple disease areas as well as new insights in tissue imaging. We'll also be sharing our latest innovations for mass cytometry research, including results from our recently announced [Maxpar® Direct Immune Profiling Assay™](#)"

Program Highlights

The Summit will open each day with presentations from leading translational and clinical researchers who are using mass cytometry and Imaging Mass Cytometry™ (IMC™) to uncover new insights in the immune system and cancer. Among the notable presentations:

- Petter Brodin, MD, PhD, Karolinska University Hospital, will present a systems-level view of the human immune system that was developed using mass cytometry.
- James Wing, PhD, Osaka University, will outline findings characterizing the function and phenotype of regulatory T cells through mass cytometry.
- Gregory Behbehani, MD, PhD, Ohio State University, will show how mass cytometry was used to characterize acute myeloid leukemia (AML).
- Thomas Ashhurst, BSc, University of Sydney and Centenary Institute, will present combined mass cytometry and IMC results profiling immune cell infiltration in the central nervous system.
- Hartland Jackson, PhD, University of Zurich, will speak on the pathology landscape of breast cancer as revealed using IMC.

Two highly anticipated panel discussions will follow the plenary session on the first day. The first, Building a Strong Core, will be led by experienced core facility directors who will share their expertise and perspectives on successfully building and maintaining mass cytometry services in both academic and industry settings. In the second panel discussion, Best Practices for Mass Cytometry in Translational and Clinical Research, experienced investigators will share key insights and best practices for integrating mass cytometry into translational and clinical research studies. Panelists for these two sessions were selected from leading research institutions including Stanford University, University of Texas MD Anderson Cancer Center, Roche Innovation Center Zurich, Karolinska University Hospital and VU University Medical Center Amsterdam.

On the second day, researchers will share novel applications developed using mass cytometry. Presentations will include new applications for CRISPR screening by Adeeb Rahman, PhD, of Icahn School of Medicine at Mount Sinai, epigenetic analysis by Alex Kuo, PhD, of Stanford University, and protein synthesis monitoring by Mark Nitz, PhD, of the University of Toronto. The program will conclude with a set of interactive mass cytometry and IMC data analysis workshops designed and led by academic experts and commercial providers.

The Summit will immediately precede the 34th Congress of the International Society for Advancement of Cytometry (CYTO), which begins June 22 in Vancouver.

Registration

Attendance is free and open to Fluidigm customers and those interested in using mass cytometry or IMC in their own laboratories. Advanced [registration](#) is highly recommended as space is limited.

About Fluidigm

Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit [fluidigm.com](#).

Fluidigm, the Fluidigm logo, CyTOF, Maxpar, Direct, Imaging Mass Cytometry, IMC and Immune Profiling Assay are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective

owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statement for Fluidigm

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding research applications for mass cytometry and the potential benefits of Fluidigm products for such research. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm's business and operating results is contained in the Fluidigm Annual Report on Form 10-K for the year ended December 31, 2018, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

Contacts:

Media:

Michaeline Bunting
Senior Director, Marketing
650 737 4190
michaeline.bunting@fluidigm.com

Investors:

Agnes Lee
Vice President, Investor Relations
650 416 7423
agnes.lee@fluidigm.com

 [LogoPressRelease.jpg](#)

Source: Fluidigm Corporation